Endothelin Receptor Antagonism and Renin Inhibition as Treatment Options for Scleroderma Kidney

American Journal of Kidney Diseases

Volumn 54, Issue 4, 2009, Pages 726-731

  Dhaun, Neeraj ^a   MacIntyre, Iain M ^a   Bellamy, Christopher O C ^a   Kluth, David C ^a  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

endothelin antagonism; renin inhibition; Scleroderma renal crisis

Indexed keywords

ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BENDROFLUMETHIAZIDE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR ANTAGONIST; FUROSEMIDE; IRBESARTAN; METHOTREXATE; NIFEDIPINE; PREDNISOLONE; RENIN INHIBITOR; SITAXSENTAN; WARFARIN; AMIDE; ANTIHYPERTENSIVE AGENT; BIOLOGICAL MARKER; ENDOTHELIN RECEPTOR; FUMARIC ACID DERIVATIVE; ISOXAZOLE DERIVATIVE; RENIN; THIOPHENE DERIVATIVE;

ADULT; ARTERIOSCLEROSIS; ARTHRALGIA; ARTICLE; BLOOD PRESSURE REGULATION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONNECTIVE TISSUE DISEASE; COUGHING; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG TOLERANCE; DYSPNEA; ECHOCARDIOGRAPHY; FEMALE; HEART SOUND; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY TUBULE DISORDER; LABORATORY TEST; LONG TERM CARE; LUMINAL THROMBOSIS; LUNG FIBROSIS; PATHOLOGY; PHYSICAL EXAMINATION; PROTEINURIA; PULMONARY HYPERTENSION; RENAL PROTECTION; SCLERODERMA; SCLERODERMA RENAL CRISIS; SCLERODERMAL RENAL CRISIS; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION; VASCULITIS; ATROPHY; BIOPSY; BLOOD; CHRONIC KIDNEY FAILURE; DRUG ANTAGONISM; FIBROSIS; IMMUNOLOGY; KIDNEY; METABOLISM; MIDDLE AGED; RENOVASCULAR HYPERTENSION; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME;

AMIDES; ANTIHYPERTENSIVE AGENTS; ATROPHY; BIOLOGICAL MARKERS; BIOPSY; FEMALE; FIBROSIS; FUMARATES; HUMANS; HYPERTENSION, RENAL; ISOXAZOLES; KIDNEY; MIDDLE AGED; PROTEINURIA; PULMONARY FIBROSIS; RECEPTORS, ENDOTHELIN; RENAL INSUFFICIENCY, CHRONIC; RENIN; SCLERODERMA, SYSTEMIC; THIOPHENES; TREATMENT OUTCOME;

EID: 70349578956     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2009.02.015     Document Type: Article

References (23)

1. Penn H., Howie A.J., Kingdon E.J., et al. Scleroderma renal crisis: Patient characteristics and long-term outcomes. QJM 100 (2007) 485-494
2. Medsger Jr. T.A., Masi A.T., Rodnan G.P., Benedek T.G., and Robinson H. Survival with systemic sclerosis (scleroderma). A life-table analysis of clinical and demographic factors in 309 patients. Ann Intern Med 75 (1971) 369-376
3. Medsger Jr. T.A., and Masi A.T. Survival with scleroderma. II. A life-table analysis of clinical and demographic factors in 358 male U.S. veteran patients. J Chronic Dis 26 (1973) 647-660
4. Denton C.P. Renal manifestations of systemic sclerosis-Clinical features and outcome assessment. Rheumatology 47 (2008) 54-56
5. Bunn C.C., Denton C.P., Shi-Wen X., Knight C., and Black C.M. Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis. Br J Rheumatol 3 (1998) 15-20
6. Steen V.D., and Medsger Jr. T.A. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 41 (1998) 1613-1619
7. Teixeira L., Mouthon L., Mahr A., et al. Mortality and risk factors of scleroderma renal crisis: A French retrospective study of 50 patients. Ann Rheum Dis 67 (2008) 110-116
8. Steen V.D., and Medsger T.A. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 66 (2007) 940-944
9. Yanagisawa M., Kurihara H., Kimura S., et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332 (1988) 411-415
10. Dhaun N., Goddard J., and Webb D.J. The endothelin system and its antagonism in chronic kidney disease. J Am Soc Nephrol 17 (2006) 943-955
11. Dhaun N., Pollock D.M., Goddard J., and Webb D.J. Selective and mixed endothelin receptor antagonism in cardiovascular disease. Trends Pharmacol Sci 28 (2007) 573-579
12. Vancheeswaran R., Magoulas T., Efrat G., et al. Circulating endothelin-1 levels in systemic sclerosis subsets-A marker of fibrosis or vascular dysfunction?. J Rheumatol 21 (1994) 1838-1844
13. Abraham D.J., Vancheeswaran R., Dashwood M.R., et al. Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am J Pathol 151 (1997) 831-841
14. Korn J.H., Mayes M., Matucci Cerinic M., et al. Digital ulcers in systemic sclerosis: Prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 50 (2004) 3985-3993
15. http://clinicaltrials.gov/ct2/show/NCT00725361?term=scleroderma&rank =31 Accessed January 25, 2009
16. http://clinicaltrials.gov/ct2/show/NCT00391443?term=scleroderma&rank =82 Accessed January 25, 2009
17. Goddard J., Johnston N.R., Hand M.F., et al. Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: A comparison of selective and combined endothelin receptor blockade. Circulation 109 (2004) 1186-1193
18. Goddard J., Eckhart C., Johnston N.R., Cumming A.D., Rankin A.J., and Webb D.J. Endothelin A receptor antagonism and angiotensin-converting enzyme inhibition are synergistic via an endothelin B receptor-mediated and nitric oxide-dependent mechanism. J Am Soc Nephrol 15 (2004) 2601-2610
19. Gradman A.H., and Kad R. Renin inhibition in hypertension. J Am Coll Cardiol 51 (2008) 519-528
20. Parving H.H., Persson F., Lewis J.B., Lewis E.J., and Hollenberg N.K. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 358 (2008) 2433-2446
21. Rajendran P.R., and Molitor J.A. Resolution of hypertensive encephalopathy and scleroderma renal crisis with an angiotensin receptor blocker. J Clin Rheumatol 11 (2005) 205-208
22. Caskey F.J., Thacker E.J., Johnston P.A., and Barnes J.N. Failure of losartan to control blood pressure in scleroderma renal crisis. Lancet 349 (1997) 620
23. Steen V., and DeMarco P. Complications in the use of angiotensin receptor blockers in the treatment of scleroderma renal crisis. Arthritis Rheum 44 (2001) 397